The Trump administration formally withdrew that rule on Tuesday, allowing pharmacists to refuse to stock or dispense misoprostol and methotrexate, despite their other uses. Mifepristone was removed from the Biden rule in 2023, after a lawsuit involving anti-abortion litigators at the arch-conservative Alliance Defending Freedom (ADF) in a case that was subsequently dismissed. I asked the two leading pharmacies in the United States—CVS and Walgreens—if they will continue to stock and dispense methotrexate. A spokesperson from CVS told me that “all our pharmacies continue to stock and dispense methotrexate where legally permissible.” Walgreens did not respond by the time of publication. It’s unclear how challenging filling methotrexate prescriptions for chronic illnesses remained under the Biden rule, but it will almost certainly become more difficult without it.